You are here: Home » News-CM » Companies » News
Business Standard

Lupin receives Health Canada approval for Propranolol Hydrochloride ER capsules

Capital Market 

Lupin announced that it has received approval for its Propranolol Hydrochloride Extended-Release (ER) Capsules, 60 mg, 80 mg, 120 mg and 160 mg from Health Canada.

Lupin is the first generic company to receive an approval for generic lnderal ® - LA Capsules for the Canadian market and the product has been approved and will be manufactured from Lupin's Pithampur Unit-2 Facility.

Lupin's Propranolol Hydrochloride Extended-Release (ER) Capsules, 60 mg, 80 mg, 120 mg and 160 mg, are the generic version of lnderal® LA Capsules, 60 mg, 80 mg, 120 mg and 160 mg of Pfizer Canada ULC, and are indicated in the treatment of hypertension and for the prophylaxis of angina pectoris.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Fri, September 13 2019. 18:00 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU